Statin OTC Switch Debate Reflects Poorly On Physicians - FDA's Woodcock

The discussion of switching cholesterol agents to over-the-counter status may reflect the failure of physicians to provide adequate counseling to patients, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the agency's OTC switch public hearing June 29.